BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 35109850)

  • 21. Base-resolution methylomes of gliomas bearing histone H3.3 mutations reveal a G34 mutant-specific signature shared with bone tumors.
    Sangatsuda Y; Miura F; Araki H; Mizoguchi M; Hata N; Kuga D; Hatae R; Akagi Y; Amemiya T; Fujioka Y; Arai Y; Yoshida A; Shibata T; Yoshimoto K; Iihara K; Ito T
    Sci Rep; 2020 Sep; 10(1):16162. PubMed ID: 32999376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Significance of H3K27M Mutation in "Nonmidline" High-Grade Gliomas of Cerebral Hemispheres.
    La Rocca G; Sabatino G; Altieri R; Signorelli F; Ricciardi L; Gessi M; Della Pepa GM
    World Neurosurg; 2019 Nov; 131():174-176. PubMed ID: 31415896
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Utility of arterial spin labeling for objective assessment of intratumoral microvessels in diffuse hemispheric glioma, H3 G34R-mutant: A case report and literature review.
    Kitakami K; Beppu T; Sato Y; Kurose A; Ogasawara K
    Radiol Case Rep; 2023 Mar; 18(3):856-861. PubMed ID: 36589502
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor mutational burden is associated with poor outcomes in diffuse glioma.
    Wang L; Ge J; Lan Y; Shi Y; Luo Y; Tan Y; Liang M; Deng S; Zhang X; Wang W; Tan Y; Xu Y; Luo T
    BMC Cancer; 2020 Mar; 20(1):213. PubMed ID: 32164609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location.
    Castel D; Philippe C; Kergrohen T; Sill M; Merlevede J; Barret E; Puget S; Sainte-Rose C; Kramm CM; Jones C; Varlet P; Pfister SM; Grill J; Jones DTW; Debily MA
    Acta Neuropathol Commun; 2018 Nov; 6(1):117. PubMed ID: 30396367
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiological and Immunostaining Characteristics of H3.3 G34R-Mutant Glioma: A Report of 3 Cases and Review of the Literature.
    Onishi S; Amatya VJ; Karlowee V; Takeshima Y; Sugiyama K; Kurisu K; Yamasaki F
    Pediatr Neurosurg; 2020; 55(5):319-325. PubMed ID: 33227796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular profiling of pre- and post-treatment pediatric high-grade astrocytomas reveals acquired increased tumor mutation burden in a subset of recurrences.
    Wood MD; Beadling C; Neff T; Moore S; Harrington CA; Baird L; Corless C
    Acta Neuropathol Commun; 2023 Sep; 11(1):143. PubMed ID: 37670377
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence and clinicopathological features of H3.3 G34-mutant high-grade gliomas: a retrospective study of 411 consecutive glioma cases in a single institution.
    Yoshimoto K; Hatae R; Sangatsuda Y; Suzuki SO; Hata N; Akagi Y; Kuga D; Hideki M; Yamashita K; Togao O; Hiwatashi A; Iwaki T; Mizoguchi M; Iihara K
    Brain Tumor Pathol; 2017 Jul; 34(3):103-112. PubMed ID: 28447171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of prognostic markers in diffuse midline gliomas H3K27M-mutant.
    Dufour C; Perbet R; Leblond P; Vasseur R; Stechly L; Pierache A; Reyns N; Touzet G; Le Rhun E; Vinchon M; Maurage CA; Escande F; Renaud F
    Brain Pathol; 2020 Jan; 30(1):179-190. PubMed ID: 31348837
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genomic profiling and prognostic factors of H3 K27M-mutant spinal cord diffuse glioma.
    Chai RC; Yan H; An SY; Pang B; Chen HY; Mu QH; Zhang KN; Zhang YW; Liu YQ; Liu X; Zhao Z; Jiang T; Wang YZ; Jia WQ
    Brain Pathol; 2023 Jul; 33(4):e13153. PubMed ID: 36751054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas.
    Fontebasso AM; Schwartzentruber J; Khuong-Quang DA; Liu XY; Sturm D; Korshunov A; Jones DT; Witt H; Kool M; Albrecht S; Fleming A; Hadjadj D; Busche S; Lepage P; Montpetit A; Staffa A; Gerges N; Zakrzewska M; Zakrzewski K; Liberski PP; Hauser P; Garami M; Klekner A; Bognar L; Zadeh G; Faury D; Pfister SM; Jabado N; Majewski J
    Acta Neuropathol; 2013 May; 125(5):659-69. PubMed ID: 23417712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.
    Karremann M; Gielen GH; Hoffmann M; Wiese M; Colditz N; Warmuth-Metz M; Bison B; Claviez A; van Vuurden DG; von Bueren AO; Gessi M; Kühnle I; Hans VH; Benesch M; Sturm D; Kortmann RD; Waha A; Pietsch T; Kramm CM
    Neuro Oncol; 2018 Jan; 20(1):123-131. PubMed ID: 29016894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diffuse midline glioma-H3K27M mutant. A novel entity with a defining and specific IHC marker.
    Agarwal P; Aiyer HM
    Indian J Pathol Microbiol; 2021; 64(2):351-353. PubMed ID: 33851633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diffuse hemispheric glioma, H3 G34-mutant: Genomic landscape of a new tumor entity and prospects for targeted therapy.
    Lucas CG; Mueller S; Reddy A; Taylor JW; Oberheim Bush NA; Clarke JL; Chang SM; Gupta N; Berger MS; Perry A; Phillips JJ; Solomon DA
    Neuro Oncol; 2021 Nov; 23(11):1974-1976. PubMed ID: 34519829
    [No Abstract]   [Full Text] [Related]  

  • 35. Cerebral hemispheric glioblastoma with PNET-like morphology and histone H3.3 G34 mutation in younger patients: Report of three rare cases and diagnostic pitfalls.
    Cheng Y; Bao W; Wu Q
    Indian J Pathol Microbiol; 2020; 63(2):262-266. PubMed ID: 32317528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single-cell RNA sequencing of anaplastic ependymoma and H3K27M-mutant diffuse midline glioma.
    Zang D; Dong Z; Liu Y; Chen Q
    BMC Neurol; 2024 Feb; 24(1):74. PubMed ID: 38383423
    [TBL] [Abstract][Full Text] [Related]  

  • 37. H3.3-G34 mutations impair DNA repair and promote cGAS/STING-mediated immune responses in pediatric high-grade glioma models.
    Haase S; Banerjee K; Mujeeb AA; Hartlage CS; Núñez FM; Núñez FJ; Alghamri MS; Kadiyala P; Carney S; Barissi MN; Taher AW; Brumley EK; Thompson S; Dreyer JT; Alindogan CT; Garcia-Fabiani MB; Comba A; Venneti S; Ravikumar V; Koschmann C; Carcaboso ÁM; Vinci M; Rao A; Yu JS; Lowenstein PR; Castro MG
    J Clin Invest; 2022 Nov; 132(22):. PubMed ID: 36125896
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Four methods to analyze H3K27M mutation in diffuse midline gliomas.
    Zhao H; Fang X; Xue B
    Pathol Res Pract; 2020 Sep; 216(9):153065. PubMed ID: 32825938
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic and clinical characterization of B7-H3 (CD276) expression and epigenetic regulation in diffuse brain glioma.
    Wang Z; Wang Z; Zhang C; Liu X; Li G; Liu S; Sun L; Liang J; Hu H; Liu Y; Zhang W; Jiang T
    Cancer Sci; 2018 Sep; 109(9):2697-2705. PubMed ID: 30027617
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High frequency of H3 K27M mutations in adult midline gliomas.
    Ebrahimi A; Skardelly M; Schuhmann MU; Ebinger M; Reuss D; Neumann M; Tabatabai G; Kohlhof-Meinecke P; Schittenhelm J
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):839-850. PubMed ID: 30610375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.